Aktuelle Tagungsinformationen
News and Updates
Anmeldung zur Tagung
Registration
Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Collateral Events
Rahmenprogramm
Social program
Jubiläumsparty
Jubilee Party
DOG Information
DOG Information
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Ausstellerliste
Exhibitors
Sponsoren
Sponsors
Teilnahmegebühren
Registration fees
Impressum
DOG Homepage
Intraocular Injection of Triamcinolone Acetonide as Treatment of Progressive Exudative Age-related Macular Degeneration
1Kreissig I., 2Degenring R. F., 2Söfker A., 2Hugger P., 2Sauder G., 2Panda-Jonas S., 2Jonas J. B.,
1Eberhard-Karls-Universität Tübingen, Universitäts-Augenklinik, Breuningerbau (Tübingen)
2Ruprecht-Karls-Universität Heidelberg, Fakultät für klinische Medizin Mannheim, Augenklinik (Mannheim)
Purpose: To evaluate therapeutic effect and complications of intravitreal injections of crystalline triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration.
Method: The prospective non-randomized comparative clinical interventional study included all 84 patients (88 eyes) who presented with progressive exudative age-related macular degeneration, and who received an intravitreal injection of 25 mg of crystalline triamcinolone acetonide. Mean follow-up time was 3.92 ± 3.18 months.
Results: Visual acuity increased significantly (P=0.001) from 0.16 ± 0.12 to a maximum of 0.22 ± 0.16. Postoperative visual acuity was highest two to four months after the injection. Fifty-three (60.2%) eyes gained in visual acuity, and 16 (18.2%) eyes lost in visual acuity. After three months of follow-up, 5 (11.1%) out of 45 eyes showed a visual loss of three lines, and 9 (20%) eyes showed an improvement of at least three lines. Intraocular pressure increased significantly (P=0.001) from 15.3 ± 2.9 mm Hg at baseline to a maximal value of 22.2 ± 9.0 mm Hg (range, 12 - 64 mm Hg). Towards study end, intraocular pressure decreased significantly (P=0.001) to 18.0 ± 4.8 mm Hg (range, 10 - 34 mm Hg). During the study period, intraocular pressure exceeded 21 mm Hg in 35 (39.8%) of the 88 eyes. In all but one of these eyes, intraocular pressure could be normalized by topical antiglaucomatous medication.
Conclusions: The results suggest that the intravitreal injection of 25 mg of crystalline triamcinolone acetonide as a therapeutic option for progressive exudative age-related macular degeneration may be further evaluated in prospective randomized studies.